.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC11_Siltuximab.Siltuximab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC11_Siltuximab.Siltuximab| name: | Siltuximab |
| ATC code: | L04AC11 | route: | intravenous |
| n-compartments | 2 |
Siltuximab is a chimeric (human-murine) monoclonal antibody that binds to human interleukin-6 (IL-6), a pro-inflammatory cytokine implicated in various inflammatory and neoplastic conditions. It is approved for the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV)-negative and human herpesvirus-8 (HHV-8)-negative.
Population pharmacokinetics in adult patients (both sexes) with multicentric Castleman’s disease or solid tumors, receiving doses of siltuximab (11 mg/kg) by intravenous infusion.
Xu, Z, et al., & Zhou, H (2011). Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. British journal of clinical pharmacology 72(2) 270–281. DOI:10.1111/j.1365-2125.2011.03964.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/21392075